496 related articles for article (PubMed ID: 21288774)
1. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.
Harrison L; Melvin A; Fiscus S; Saidi Y; Nastouli E; Harper L; Compagnucci A; Babiker A; McKinney R; Gibb D; Tudor-Williams G;
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):42-53. PubMed ID: 26322666
[TBL] [Abstract][Full Text] [Related]
3. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Hakim JG; Thompson J; Kityo C; Hoppe A; Kambugu A; van Oosterhout JJ; Lugemwa A; Siika A; Mwebaze R; Mweemba A; Abongomera G; Thomason MJ; Easterbrook P; Mugyenyi P; Walker AS; Paton NI;
Lancet Infect Dis; 2018 Jan; 18(1):47-57. PubMed ID: 29108797
[TBL] [Abstract][Full Text] [Related]
5. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
[TBL] [Abstract][Full Text] [Related]
6. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI; Kityo C; Thompson J; Nankya I; Bagenda L; Hoppe A; Hakim J; Kambugu A; van Oosterhout JJ; Kiconco M; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS;
Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562
[TBL] [Abstract][Full Text] [Related]
7. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
ARROW Trial team
Lancet; 2013 Apr; 381(9875):1391-1403. PubMed ID: 23473847
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
[TBL] [Abstract][Full Text] [Related]
9. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
10. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
[TBL] [Abstract][Full Text] [Related]
11. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Namane T; Mpholo T; Battegay M; Klimkait T; Labhardt ND
PLoS Med; 2020 Sep; 17(9):e1003325. PubMed ID: 32936795
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
13. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Aboud M; Kaplan R; Lombaard J; Zhang F; Hidalgo JA; Mamedova E; Losso MH; Chetchotisakd P; Brites C; Sievers J; Brown D; Hopking J; Underwood M; Nascimento MC; Punekar Y; Gartland M; Smith K
Lancet Infect Dis; 2019 Mar; 19(3):253-264. PubMed ID: 30732940
[TBL] [Abstract][Full Text] [Related]
15. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
Clin Infect Dis; 2018 Feb; 66(4):594-603. PubMed ID: 29029056
[TBL] [Abstract][Full Text] [Related]
16. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
[TBL] [Abstract][Full Text] [Related]
17. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
Pozniak A; Markowitz M; Mills A; Stellbrink HJ; Antela A; Domingo P; Girard PM; Henry K; Nguyen T; Piontkowsky D; Garner W; White K; Guyer B
Lancet Infect Dis; 2014 Jul; 14(7):590-9. PubMed ID: 24908550
[TBL] [Abstract][Full Text] [Related]
18. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D
D2EFT Study Group
Lancet HIV; 2024 May; ():. PubMed ID: 38788744
[TBL] [Abstract][Full Text] [Related]
20. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
